Ariel Dora Stern

Harvard Business School

Associate Professor

Morgan Hall 433

Harvard Business School

Boston, MA MASSACHUSETTS 02163

United States

http://www.hbs.edu/astern

SCHOLARLY PAPERS

9

DOWNLOADS

774

SSRN CITATIONS
Rank 20,874

SSRN RANKINGS

Top 20,874

in Total Papers Citations

38

CROSSREF CITATIONS

11

Scholarly Papers (9)

1.

The Impact of the Entry of Biosimilars: Evidence from Europe

Morton, Fiona M. Scott, Ariel Dora Stern, and Scott Stern. "The impact of the entry of biosimilars: evidence from Europe." Review of Industrial Organization 53, no. 1 (2018): 173-210.
Number of pages: 71 Posted: 24 Jul 2016 Last Revised: 04 May 2019
Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Yale School of Management, Harvard Business School and Massachusetts Institute of Technology (MIT) - Sloan School of Management
Downloads 375 (97,719)
Citation 8

Abstract:

Loading...

Biosimilars; Biologics; Pharmaceutical Competition; Health Care Spending; Innovation

2.

Recalls, Innovation, and Competitor Response: Evidence from Medical Device Firms

Harvard Business School Working Paper 19-028 , Georgetown McDonough School of Business Research Paper No. 3251630
Number of pages: 49 Posted: 12 Oct 2018 Last Revised: 31 Mar 2019
George Ball, Jeffrey T. Macher and Ariel Dora Stern
Operations and Decision Technologies Dept, Kelley School of Business, Indiana University, Georgetown University - McDonough School of Business - Strategy, Economics and Policy and Harvard Business School
Downloads 171 (213,923)
Citation 3

Abstract:

Loading...

3.

Pioneer (Dis-)advantages in Markets for Technology

Harvard Business School Working Paper No. 19-043
Number of pages: 42 Posted: 01 May 2019 Last Revised: 18 Mar 2020
Moritz Fischer, Joachim Henkel and Ariel Dora Stern
Technische Universität München (TUM), TUM School of Management - Technical University of Munich (TUM) and Harvard Business School
Downloads 71 (394,994)

Abstract:

Loading...

First-Mover Advantages, Markets for Technology, M&A, Technology Acquisition, Medical Devices

4.

Innovation Under Regulatory Uncertainty: Evidence from Medical Technology

Stern, A.D., Innovation under Regulatory Uncertainty: Evidence from Medical Technology, Journal of Public Economics. Final version published online: 06-Dec-2016. DOI information: 10.1016/j.jpubeco.2016.11.010, Journal of Public Economics, Vol. 145, 2017
Number of pages: 20 Posted: 17 Oct 2016 Last Revised: 13 Aug 2018
Ariel Dora Stern
Harvard Business School
Downloads 62 (423,922)
Citation 12

Abstract:

Loading...

Regulation, Innovation, FDA, Medical Devices

5.

Physician Beliefs and Patient Preferences: A New Look at Regional Variation in Health Care Spending

NBER Working Paper No. w19320
Number of pages: 64 Posted: 17 Aug 2013 Last Revised: 17 Apr 2021
Harvard University - Department of Economics, Dartmouth College - Department of Economics, Harvard Business School and Geisel School of Medicine at Dartmouth
Downloads 60 (430,874)
Citation 24

Abstract:

Loading...

6.

Characterizing the Drug Development Pipeline for Precision Medicines

NBER Working Paper No. w24026
Number of pages: 70 Posted: 20 Nov 2017 Last Revised: 24 Feb 2021
Amitabh Chandra, Craig L. Garthwaite and Ariel Dora Stern
Harvard University - Harvard Kennedy School (HKS), Northwestern University - Department of Management & Strategy and Harvard Business School
Downloads 19 (634,256)
Citation 3

Abstract:

Loading...

7.

Editors are Gatekeepers of Science, but Individual Editors Don’t Matter Much

Number of pages: 39 Posted: 12 Jul 2021 Last Revised: 13 Jul 2021
Joshua Krieger, Kyle Myers and Ariel Dora Stern
Harvard University - Business School (HBS), Harvard University - Technology & Operations Management Unit and Harvard Business School
Downloads 13 (677,767)

Abstract:

Loading...

8.

Which Markets (Don&Apos;T) Drive Pharmaceutical Innovation? Evidence from U.S. Medicaid Expansions

NBER Working Paper No. w28755
Number of pages: 54 Posted: 10 May 2021 Last Revised: 20 Jul 2021
Craig Garthwaite, Rebecca Sachs and Ariel Dora Stern
Northwestern University, George Washington University - Law School and Harvard Business School
Downloads 3 (755,499)
  • Add to Cart

Abstract:

Loading...

9.

Germany’s Digital Health Reforms in the COVID-19 Era: Lessons and Opportunities for Other Countries

npj Digit. Med. 3, 94 (2020). https://doi.org/10.1038/s41746-020-0306-7
Posted: 09 Jul 2021
Sara Gerke, Ariel Dora Stern and Timo Minssen
Pennsylvania State University, Dickinson Law, Harvard Business School and University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Abstract:

Loading...

Digital Health, Germany, Apps, Digital Healthcare Act